Trust Point Inc. Acquires 290 Shares of Eli Lilly and Company (NYSE:LLY)

Trust Point Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,050 shares of the company’s stock after acquiring an additional 290 shares during the quarter. Trust Point Inc.’s holdings in Eli Lilly and Company were worth $3,588,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Aaron Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 14.6% in the third quarter. Aaron Wealth Advisors LLC now owns 5,404 shares of the company’s stock worth $4,788,000 after purchasing an additional 690 shares during the last quarter. Stonegate Investment Group LLC increased its holdings in shares of Eli Lilly and Company by 1.5% in the third quarter. Stonegate Investment Group LLC now owns 56,999 shares of the company’s stock worth $50,498,000 after buying an additional 862 shares during the period. Claro Advisors LLC increased its holdings in shares of Eli Lilly and Company by 19.0% in the third quarter. Claro Advisors LLC now owns 4,556 shares of the company’s stock worth $4,036,000 after buying an additional 726 shares during the period. V Square Quantitative Management LLC lifted its stake in shares of Eli Lilly and Company by 9.8% in the 3rd quarter. V Square Quantitative Management LLC now owns 14,168 shares of the company’s stock valued at $12,552,000 after acquiring an additional 1,266 shares during the last quarter. Finally, CHB Investment Group LLC purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at about $2,764,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday. They issued an “outperform” rating and a $1,100.00 target price on the stock. Bank of America increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Finally, Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Stock Up 0.1 %

NYSE:LLY opened at $917.86 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The firm’s 50-day moving average price is $921.21 and its 200-day moving average price is $857.37. The company has a market capitalization of $872.34 billion, a PE ratio of 135.18, a P/E/G ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.